This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
by Zacks Equity Research
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
by Zacks Equity Research
Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 0.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
by Zacks Equity Research
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.
Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Implied Volatility Surging for Ironwood (IRWD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.
Why Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
by Zacks Equity Research
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 24% and 3.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More
by Zacks Equity Research
Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.
Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion
by Zacks Equity Research
Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.
Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
by Zacks Equity Research
Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
by Zacks Equity Research
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
by Zacks Equity Research
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 4.17% and 4.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
by Zacks Equity Research
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others
by Zacks Equity Research
Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
by Zacks Equity Research
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.